Evelo Biosciences on Monday set terms for its planned initial public offering, saying it will offer 5.3 million shares priced at $15 to $17 each. The company is planning to list on Nasdaq under the ticker symbol "EVLO." Morgan Stanley, Cowen and BMO Capital Markets are lead underwriters on the deal with JMP Securities acting as co-manager.